Key result
A woman with neuroleptic malignant syndrome presenting with elevated CRP and ESR during the COVID-19 pandemic was successfully managed with electroconvulsive therapy and lorazepam.
Why the study?
Reports of co-occurrence of catatonia, neuroleptic malignant syndrome, and COVID-19 with elevated acute phase reactants create diagnostic dilemmas during the COVID-19 pandemic.
Case Report (n=1)
Highlights the diagnostic dilemma of elevated acute phase reactants in NMS during the COVID-19 pandemic.
Answers are grounded in this paper and cite their sources.
May prompt inflammatory marker checks in NMS; Level 5 data leaves open diagnostic or prognostic value.
Key Clinical Message: In some patients, neuroleptic malignant syndrome is accompanied significant high levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP). Abstract: Neuroleptic malignant syndrome (NMS) is an idiosyncratic life-threatening adverse reaction and usually triggered in response to antipsychotic drugs. In addition, leukocytosis and increased muscle enzymes levels (especially creatine phosphokinase) are observed in NMS. In addition, a transient increase in different types of acute phase reactants in NMS has been mentioned. This article describes a woman treated with haloperidol, perphenazine, escitalopram, and alprazolam because she developed catatonic symptoms after psychological stress. She suffered from NMS symptoms and had elevated CRP and ESR levels, among other signs and symptoms. Given the COVID-19 pandemic and reports of co-occurrence of catatonia and NMS and COVID-19 and elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), this patient was a diagnostic dilemma. After consultation with the consultation-liaison psychiatry units, she was managed adequately with electroconvulsive therapy and lorazepam.
No takes yet. Share an insight, caveat, or question.
Elyasi et al. (2023) conducted a case report in Neuroleptic malignant syndrome (n=1). Electroconvulsive therapy and lorazepam was evaluated. A woman with neuroleptic malignant syndrome presenting with elevated CRP and ESR during the COVID-19 pandemic was successfully managed with electroconvulsive therapy and lorazepam.
Synapse has enriched 10 related papers. Consider them for comparative context: